C 6161
Alternative Names: C-6161Latest Information Update: 18 Feb 2008
At a glance
- Originator Merck & Co
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 07 Mar 2005 Phase-I clinical trials in Parkinson's disease in USA (unspecified route)